TMDX Stock Overview
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
TransMedics Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$89.25 |
| 52 Week High | US$99.63 |
| 52 Week Low | US$36.42 |
| Beta | 1.98 |
| 1 Month Change | 19.81% |
| 3 Month Change | 3.24% |
| 1 Year Change | 13.55% |
| 3 Year Change | 209.68% |
| 5 Year Change | 299.15% |
| Change since IPO | 299.15% |
Recent News & Updates
TransMedics Group, Inc. (NASDAQ:TMDX) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Apr 24
TransMedics Group: Founder Led Company With Solid Potential
Apr 19Is TransMedics Group (NASDAQ:TMDX) Using Too Much Debt?
Apr 11Recent updates
TransMedics Group, Inc. (NASDAQ:TMDX) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Apr 24TransMedics Group: Founder Led Company With Solid Potential
Apr 19Is TransMedics Group (NASDAQ:TMDX) Using Too Much Debt?
Apr 11TransMedics Group: Emerging Medical Device Market Leader With A Long Growth Runway
Mar 19TransMedics Group: Huge Opportunity In Organ Transplants
Mar 12TransMedics: A Very Expensive Growth Stock
Feb 07With TransMedics Group, Inc. (NASDAQ:TMDX) It Looks Like You'll Get What You Pay For
Jan 23Calculating The Fair Value Of TransMedics Group, Inc. (NASDAQ:TMDX)
Jan 02Does TransMedics Group (NASDAQ:TMDX) Have A Healthy Balance Sheet?
Nov 05This Just In: Analysts Are Boosting Their TransMedics Group, Inc. (NASDAQ:TMDX) Outlook for This Year
Aug 06TransMedics Group (NASDAQ:TMDX) Has Debt But No Earnings; Should You Worry?
Aug 02TransMedics Group, Inc. (NASDAQ:TMDX) Not Lagging Industry On Growth Or Pricing
Jun 29Brokers Are Upgrading Their Views On TransMedics Group, Inc. (NASDAQ:TMDX) With These New Forecasts
May 06Is TransMedics Group (NASDAQ:TMDX) Using Too Much Debt?
Apr 27Estimating The Intrinsic Value Of TransMedics Group, Inc. (NASDAQ:TMDX)
Apr 09Is TransMedics Group (NASDAQ:TMDX) A Risky Investment?
Jan 16TransMedics: Game Changer Technology Will Boost Revenue Growth
Oct 20TransMedics Is A Buy Following Q2 FY22 Earnings Upside
Aug 03Is TransMedics Group (NASDAQ:TMDX) Weighed On By Its Debt Load?
Jun 12TransMedics - Impressive Transformation
May 20Shareholder Returns
| TMDX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 2.3% | 1.6% | 1.0% |
| 1Y | 13.5% | -1.4% | 21.9% |
Return vs Industry: TMDX exceeded the US Medical Equipment industry which returned -0.5% over the past year.
Return vs Market: TMDX underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| TMDX volatility | |
|---|---|
| TMDX Average Weekly Movement | 8.2% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TMDX has not had significant price volatility in the past 3 months.
Volatility Over Time: TMDX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 584 | Waleed Hassanein | www.transmedics.com |
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers.
TransMedics Group, Inc. Fundamentals Summary
| TMDX fundamental statistics | |
|---|---|
| Market cap | US$2.93b |
| Earnings (TTM) | -US$25.03m |
| Revenue (TTM) | US$241.62m |
12.1x
P/S Ratio-117.1x
P/E RatioIs TMDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TMDX income statement (TTM) | |
|---|---|
| Revenue | US$241.62m |
| Cost of Revenue | US$87.53m |
| Gross Profit | US$154.09m |
| Other Expenses | US$179.12m |
| Earnings | -US$25.03m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 63.77% |
| Net Profit Margin | -10.36% |
| Debt/Equity Ratio | 368.9% |
How did TMDX perform over the long term?
See historical performance and comparison